RFL
- Rafael Holdings, Inc.
()
Overview
Company Summary
Rafael Holdings, Inc. (RFL) is a diversified holding company that focuses on acquiring and managing assets in various sectors. The company primarily operates through its subsidiary, Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals specializes in the development and commercialization of innovative cancer therapies. It focuses on creating targeted therapies that utilize nanoparticle technology and address high unmet medical needs. The company's flagship drug candidate is CPI-613, which targets the altered mitochondrial metabolism observed in many cancer cells. CPI-613 is currently being investigated in clinical trials for various types of cancer.
Beyond pharmaceuticals, Rafael Holdings also owns commercial real estate assets. The company's real estate portfolio includes assets such as office buildings, warehouse facilities, and residential properties. The company aims to generate rental income and property value appreciation from these assets.
Additionally, Rafael Holdings holds investments in other companies and ventures, providing capital and strategic support. As a diversified holding company, RFL seeks to identify opportunities across different industries, including healthcare, technology, and real estate, to maximize shareholder value.
Overall, Rafael Holdings operates in the biotechnology sector through its subsidiary Rafael Pharmaceuticals and manages a real estate portfolio. It also leverages its resources to invest in promising companies across various industries, positioning itself as a well-rounded holding company.